Alamri Aisha M, Almehman Wijdan A, Albuhairy Ali M, Alkatheeri Ayed A, Alzahrani Yahya A
Department of Pediatrics, East Jeddah Hospital, Ministry of Health, Jeddah, 23816, Saudi Arabia.
Department of Medical Microbiology, East Jeddah Hospital, Ministry of Health, Jeddah, 23816, Saudi Arabia.
Int Med Case Rep J. 2025 Sep 1;18:1135-1140. doi: 10.2147/IMCRJ.S529396. eCollection 2025.
Glecaprevir/Pibrentasvir (GLE/PIB) is approved for chronic hepatitis C treatment in both adults and pediatric patients, no data regarding crushing this drug in pediatric populations. This case series evaluate the efficacy and safety of crushed or split GLE/PIB tablets in two pediatric patients at East Jeddah Hospital, Saudi Arabia.
Two treatment-naïve pediatric patients with normal liver function received weight-based GLE/PIB for eight weeks. The first patient ingested crushed tablets with juice, while the second consumed divided tablets. Viral load, liver function, and coagulation profiles were monitored. Both patients achieved rapid viral suppression, with hepatitis C RNA undetectable or near the lower limit of quantification by day 14. Liver function tests improved, and no adverse effects were observed.
This is the first case series of successful pediatric HCV treatment using crushed or Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals split GLE/PIB. This approach may expand treatment options in resource-limited settings where pediatric formulations are unavailable.
格卡瑞韦/哌柏西利（GLE/PIB）已被批准用于成人和儿童慢性丙型肝炎的治疗，但尚无关于在儿科人群中碾碎该药物的数据。本病例系列评估了在沙特阿拉伯吉达东部医院对两名儿科患者使用碾碎或掰开的GLE/PIB片剂的疗效和安全性。
两名初治且肝功能正常的儿科患者接受了基于体重的GLE/PIB治疗，为期八周。第一名患者将片剂碾碎后与果汁一起服用，而第二名患者服用了掰开的片剂。监测病毒载量、肝功能和凝血指标。两名患者均实现了快速病毒抑制，至第14天时丙型肝炎病毒RNA检测不到或接近定量下限。肝功能检查有所改善，且未观察到不良反应。
这是首例使用碾碎或掰开的GLE/PIB成功治疗儿童丙型肝炎的病例系列。这种方法可能会在无法获得儿科剂型的资源有限环境中扩大治疗选择。
